Intravenous ketamine successfully treats treatment‐resistant catatonia in schizophrenia: A case report
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024
DOI: 10.1002/phar.4612 ↗At a glance
Fallbericht in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Written by Atif Siddiqui. Institution: Houston Methodist Hospital, Houston, Texas, USA. Major MEDLINE topics: Ketamine, Catatonia. Cited 4 times so far (Crossref); 16 references.
Abstract (original language)
Background
Benzodiazepines and electroconvulsive therapy (ECT) are mainstay treatments for catatonia, a potentially life‐threatening psychomotor syndrome characterized by a range of symptoms, including immobility, mutism, stupor, posturing, and sometimes even agitation. It can be a manifestation of various underlying psychiatric or medical conditions, such as schizophrenia, mood disorders, or neurological disorders. When conventional treatments fail to alleviate symptoms, ketamine, a dissociative anesthetic, has emerged as a potential therapeutic option for catatonia. However, its precise mechanism of action in treating catatonia remains to be fully elucidated. The use of ketamine in treating treatment‐resistant catatonia in patients with schizophrenia has not been described.
Methods
We describe a unique case of a 77‐year‐old female with schizophrenia for 15 years who presented with hallucinations, generalized weakness, immobility, stupor, and mutism consistent with severe catatonia. The electroencephalogram did not show seizures, and brain imaging was negative for stroke. Her catatonia was resistant to treatment with benzodiazepines and haloperidol. However, ECT was unavailable due to the COVID‐19 pandemic. She was successfully treated with a single intravenous infusion of ketamine administered at a dose of 0.5 mg/kg over 40 min with complete rapid recovery and remained stable as an outpatient.
Results
Intravenous ketamine single infusion may be a safe and feasible option in schizophrenia patients with drug‐resistant catatonia, particularly in patients for whom standard therapies are ineffective. However, its use should be approached cautiously due to the risk of exacerbation of psychosis in patients with schizophrenia.
Conclusions
Further research is warranted to better understand the role of ketamine in the management of catatonia in this patient population.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Houston Methodist Hospital, Houston, Texas, USA.
ORCID profiles: Atif Siddiqui
Cite
APA
Siddiqui, A. (2024). Intravenous ketamine successfully treats treatment‐resistant catatonia in schizophrenia: A case report. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.4612
Vancouver
Siddiqui A. Intravenous ketamine successfully treats treatment‐resistant catatonia in schizophrenia: A case report. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.4612
BibTeX
@article{Siddiqui2024,
author = {Siddiqui, Atif},
title = {Intravenous ketamine successfully treats treatment‐resistant catatonia in schizophrenia: A case report},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2024},
doi = {10.1002/phar.4612}
}
EUVIMED